Archive: prescription medicine

Premium
Time is running out to invest in NowRx. When we urged you to invest last November, it was a compelling opportunity. Since then, it’s gone from compelling to irresistible. Growth has taken off. And Friday is your last chance to invest in this very impressive healthcare startup. Here’s what I said when I recommended NowRx to you last November… With…
Premium

NowRx Facing “Unprecedented” Demand

By Andy Gordon on May 18, 2020

When we first recommended NowRx to you in July 2018, its valuation was $20 million. Last November, we recommended you invest in the company again at a $65 million valuation — a more than 3X increase on your original investment price. We were impressed by its execution and…